|Other Names||Fanconi anemia group C protein, Protein FACC, FANCC, FAC, FACC|
|Target/Specificity||The synthetic peptide sequence is selected from aa 538-552 of HUMAN FANCC|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Upon IFNG induction, may facilitate STAT1 activation by recruiting STAT1 to IFNGR1.|
|Cellular Location||Nucleus. Cytoplasm. Note=The major form is nuclear. The minor form is cytoplasmic|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group C.
Hartmann, L., et al. Am. J. Hum. Genet. 87(4):480-493(2010)
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Pace, P., et al. Science 329(5988):219-223(2010)
Monsees, G.M., et al. Breast Cancer Res. Treat. (2010) In press :
Palagyi, A., et al. Mol. Cancer 9, 127 (2010) :
If you have any additional inquiries please email technical services at email@example.com.